Erhan Aptullahoglu
Mohammed Howladar
Dr Jonathan Wallis
Dr Helen Marr
Professor Julie Irving
et al. | Targeting the MDM2-p53 Interaction with Siremadlin: A Promising Therapeutic Strategy for Treating TP53 Wild-Type Chronic Lymphocytic Leukemia | 2025 |
|
Erhan Aptullahoglu
Dr Sirintra Nakjang
Dr Jonathan Wallis
Dr Helen Marr
Dr Scott Marshall
et al. | RNA Sequencing Reveals Candidate Genes and Pathways Associated with Resistance to MDM2 Antagonist Idasanutlin in TP53 Wild-Type Chronic Lymphocytic Leukemia | 2024 |
|
Erhan Aptullahoglu
Dr Jonathan Wallis
Dr Helen Marr
Dr Elaine Willmore
Professor John Lunec
et al. | SF3B1 Mutations Are Associated with Resistance to Non-Genotoxic MDM2 Inhibition in Chronic Lymphocytic Leukemia | 2023 |
|
Dr Carmela Ciardullo
Erhan Aptullahoglu
Dr Laura Woodhouse
Dr Wei-Yu Lin
Dr Jonathan Wallis
et al. | Non-genotoxic MDM2 inhibition selectively induces pro-apoptotic p53 gene signature in chronic lymphocytic leukemia cells | 2019 |
|
Arman Esfandiari
Nan Wang
Dr Ahmed Mahdi
Erhan Aptullahoglu
Professor Penny Lovat
et al. | Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeuticstrategy in cutaneous melanoma | 2018 |
|
